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Children Can Be a Tough
Group to Figure Out
Perhaps the risk assessment community has
difﬁculty embracing the arena of children’s risk
because of the imposing task. Children are dif-
ﬁcult to study for a number of reasons, not the
least of which is a practical one: it is not ethi-
cally feasible to introduce chemicals of environ-
mental concern, even at trace amounts, into
infants and children. Thus, there is very little
toxicokinetic data (i.e., pharmacokinetic data
for environmental toxicants) in this age group.
One can gather data from “natural experi-
ments” in which children are exposed inadver-
tently to a pesticide or airborne chemical. The
resulting biomarker data may be useful for
investigators in assessing the extent of exposure,
but these are not the well-controlled toxico-
kinetic data one needs for building a predictive
children’s model. Another equally daunting
problem is that children are highly diverse,
stretching in deﬁnition (for the purposes of this
framework) from fetal through adolescent
stages and beyond. Generalizations and defaults
are not possible for such a sweeping range of
development. Even within a narrow age range,
there can be considerable variability, given the
rapid and variable rate of development in early
life. Thus, improving children’s risk assess-
ments through toxicokinetics is a worthwhile
endeavor but one that will be hampered by
data gaps and uncertainties.
Our goal in writing this article on toxico-
kinetic issues is to outline the toxicokinetic
questions that need to be addressed if this area
of study is to contribute to a children’s risk
assessment. We also hope to provide the reader
with some background and resources that can
help shed light on these questions by showing
where this information can ﬁt into a framework
for children’s risk assessment. We recognize
that such risk assessments also need to address
critical exposure and toxicodynamic issues, and
that in some ways these areas overlap with
toxicokinetics (Adams et al. 2000). We point
out those interfaces, but for this discussion we
will keep toxicokinetics as a separate considera-
tion in the children’s risk assessment process. 
Toxicokinetics as a key element in chil-
dren’s risk assessments. The importance of
toxicokinetics in risk assessment has been
increasing as we have learned more about how
toxicokinetic processes (especially chemical
metabolism) are involved in mechanisms of
toxicity and how these processes can differ
markedly across species. In numerous cases,
toxicokinetic analyses have allowed replace-
ment of the traditional dose metric—applied
dose per body weight per day—by a more rele-
vant internal dose metric that facilitates
extrapolation of animal dose–response data to
humans (Andersen et al. 1987; Bois et al.
1990; Hattis et al. 1993; Rao and Ginsberg
1997). Most commonly this is accomplished
with physiologically based pharmacokinetic
(PBPK) models, which simulate chemical
uptake, distribution, metabolism, and excre-
tion in both animals and humans. 
Although progress in toxicokinetics has
removed some of the uncertainty in cross-
species extrapolations in risk assessment for
adults, these principles have yet to be applied
in a systematic manner to the risk assessment
of children. This is a critical need, given that
children’s toxicokinetics differ from adults in a
number of ways: smaller body size; different
ratios of fat, muscle, and water; higher breath-
ing and metabolic rates per body weight; and
immaturity of clearance systems and enzymatic
reactions (Anderson et al. 1997; Besunder
et al. 1988; Ginsberg et al. 2002; Kearns and
Reed 1989; Renwick 1998). Another obvious
difference is that children are more diverse,
undergoing a developmental program of
growth and maturation that continuously
alters how chemicals are processed and cleared.
Thus, incorporating children’s toxicokinetics
into risk assessment is complicated by the need
to consider many developmental stages, rang-
ing from in utero to adolescence, and by the
extensive variability that can occur within each
age group.
Pharmacokinetic differences between chil-
dren and adults with respect to the clearance of
therapeutic drugs have been recognized for
years. These differences have spawned numer-
ous clinical pharmacokinetic studies for the
purpose of better titrating drug dosage to a
particular age or body size (Anderson et al.
1997; Ginsberg et al. 2002; Morselli 1989;
Renwick et al. 2000). The focus on children as
a pharmacological receptor has not been
matched by a similar focus on children as a
toxicant receptor. In large part this is because
of the lack of pediatric toxicokinetic studies, as
mentioned above. This leaves us with a
relatively rich pharmacokinetic database for
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Children’s responses to environmental toxicants will be affected by the way in which their systems
absorb, distribute, metabolize, and excrete chemicals. These toxicokinetic factors vary during
development, from in utero where maternal and placental processes play a large role, to the
neonate in which emerging metabolism and clearance pathways are key determinants.
Toxicokinetic differences between neonates and adults lead to the potential for internal dosimetry
differences and increased or decreased risk, depending on the mechanisms for toxicity and clear-
ance of a given chemical. This article raises a number of questions that need to be addressed when
conducting a toxicokinetic analysis of in utero or childhood exposures. These questions are orga-
nized into a proposed framework for conducting the assessment that involves problem formula-
tion (identiﬁcation of early life stage toxicokinetic factors and chemical-speciﬁc factors that may
raise questions/concerns for children); data analysis (development of analytic approach, construc-
tion of child/adult or child/animal dosimetry comparisons); and risk characterization (evaluation
of how children’s toxicokinetic analysis can be used to decrease uncertainties in the risk assess-
ment). The proposed approach provides a range of analytical options, from qualitative to quantita-
tive, for assessing children’s dosimetry. Further, it provides background information on a variety of
toxicokinetic factors that can vary as a function of developmental stage. For example, the ontology
of metabolizing systems is described via reference to pediatric studies involving therapeutic drugs
and evidence from in vitro enzyme studies. This type of resource information is intended to help
the assessor begin to address the issues raised in this paper. Key words: children, dosimetry, risk
assessment, toxicokinetics. Environ Health Perspect 112:272–283 (2003). doi:10.1289/ehp.6013
available via http://dx.doi.org/ [Online 25 November 2003]children but a nearly empty toxicokinetic data-
base. Challenges facing the children’s risk
assessment framework include how to combine
basic information on children’s physiologic
development with what can be learned from
children’s pharmacokinetic data sets and how
to develop an analytic process that allows us to
compare internal doses of environmental toxi-
cants between adults and children.
Proposed building blocks for a children’s
toxicokinetic assessment. In crafting a general
framework for conducting children’s risk
assessments, a 3-phase approach has been rec-
ommended that involves problem formulation,
data analysis, and risk characterization. [See
companion article by Daston et al. (2004)]. An
overview of this approach is provided in
Figure 1, which serves to organize the informa-
tion on children’s toxicokinetics into a stepwise
analytical approach. 
Phase I: Toxicokinetic Questions
in Problem Formulation 
A risk assessment of children will likely begin
with a number of questions regarding age
groups and exposures, toxicokinetic handling
of the chemical(s), and whether there are sus-
ceptible periods or unique toxic effects (toxico-
dynamic issues). These questions and the
preliminary answers developed in problem for-
mulation help to scope the remainder of the
analysis. A major toxicokinetic question likely
to arise in problem formulation is “Can early
life stages be considered as part of the overall
human variability distribution and thus be
within the 3.2-fold toxicokinetic uncertainty
factor”? This broad question can be broken
into the following more-defined areas that
should help the risk assessor better evaluate the
issues of children’s toxicokinetics:
• What types of data, resources, and analytic
approaches are needed to determine whether
a) children of certain ages experience higher
exposures because of higher ventilation rates,
cardiac outputs, or greater absorption of
chemical(s); b) children of certain ages expe-
rience a higher internal dose of parent com-
pound or active metabolite (per unit of
administered dose) because of distributional,
metabolism, or elimination factors; and
c) children of certain ages process the chemi-
cal(s) by novel toxicokinetic pathways in
order to generate metabolite proﬁles that are
qualitatively different from those of adults?
In this article we discuss these broad, scop-
ing toxicokinetic questions to provide back-
ground information and to help us consider
what kinds of resources and analyses will be
needed for their resolution.
• Does children’s toxicokinetics warrant an
uncertainty factor that differs from the cur-
rent practice of allowing an approximately
3.2-fold factor for intersubject variability in
toxicokinetics?
Noncancer risk assessments are concerned
with threshold effects, with the public health
exposure level set well below the observed
threshold seen in animal or high-exposure
human studies [U.S. EPA (U.S. Environmental
Protection Agency) 1989]. A series of uncer-
tainty factors are used to attempt to conserva-
tively cover what we do not know about risks;
the uncertainty factors lower the allowable
exposure level from the animal or human no
observable adverse effect level (NOAEL) or
benchmark dose. Prominent among these is the
interindividual variability factor, typically a 10-
fold factor. This factor results from a general
recognition that the animal species or worker
cohort from which the NOAEL is determined
rarely, if ever, represents the range of diversity
present in the human population at large. This
uncertainty factor should encompass variability
from a wide array of sources: inherited traits
and genetic polymorphisms, gender and hor-
monal differences, lifestyle factors such as
amount of stress, exercise, tobacco and alcohol
use, obesity, nutritional status, and ﬁnally, dis-
ease conditions, some of which can alter the
handling of xenobiotics. Related to this last fac-
tor is the ingestion of prescription and over-the-
counter medications, many of which can alter
the pharmacokinetics of other chemicals.
Another circumstance that this intersubject
uncertainty factor is asked to cover is age,
encompassing a range from prenatal to elderly.
As mentioned above, the noncancer
uncertainty factor is 10, which can be under-
stood to consist of a half-log factor (3.16-fold)
for toxicokinetic variability and a similar half-
log factor for pharmacodynamic variability
(Renwick 1998 ). Thus, the interindividual
variability in toxicokinetics created by the vari-
ous genetic, lifestyle, physiologic state, and age
factors must ﬁt within a 3.2-fold factor for the
default to be adequate. In other words, one
must determine whether the upper or lower
ends of the children’s distribution (e.g., low-
end metabolizers) are captured within the
bounds created by the adult central tendency
value plus or minus a 3.2-fold uncertainty fac-
tor. If not, then a special children’s uncertainty
factor or other more quantitative approaches to
characterize variability might be needed. 
It is important to point out that a similar
uncertainty factor does not exist for cancer risk
assessment. These assessments are generally
considered conservative because of the nature
of the linear low-dose modeling often used
and because interspecies scaling of the unit
risk factor employs a generic body weight
function that increases human potency relative
to that of rodents (Andersen et al. 1995;
U.S. EPA 1992). However, the lack of any
special consideration of children’s risk in can-
cer assessments leaves open the question of
whether the derived unit risks are appropriate
for all age groups. In fact, one recent cancer
risk assessment did adjust the unit risk for
child-speciﬁc factors, but this adjustment was
not based on toxicokinetics (U.S. EPA 2000).
Thus, in the absence of precedents for
using a children’s toxicokinetic analysis to
adjust cancer or noncancer assessments, a
framework is needed for doing this in a ratio-
nal and consistent manner. The hope is that
such a process will foster an understanding of
the size of adult/child differences in key toxico-
kinetic pathways relative to the amount of
interindividual variability we have come to
expect in noncancer assessments.
Phase II: Data Analysis and
Development of Risk
Assessment Approach
In this phase, chemical-speciﬁc data regarding
the fate of the chemical(s) being analyzed are
combined with children’s data relating to the
developmental proﬁle of toxicokinetic systems
(from in utero periods through adolescence).
This will foster an understanding of how chil-
dren of various ages are likely to handle the
chemical(s). Obviously, the best case is to have
metabolism and disposition data for the chemi-
cal(s) in children. However, it will be extremely
rare to ﬁnd such toxicokinetic data. Following
are some approaches to consider for filling
these data gaps:
Use of toxicokinetic data for the
chemical(s) under analysis to characterize the
major fate and transport mechanisms.
Typically, animal data, and in some cases,
adult human data also, will be available for
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Problem formulation
•  What type of assessment: (cancer vs. noncancer)?
•  Which age groups, dose routes, and target organs need to
be considered based upon exposure and toxicity information?
•  What special toxicokinetic factors in children need to be
considered?
•  What chemical-specific and age group–specific data
are available?
•  What analytic options are available?
Chemical-specific analysis
•  Evaluate chemical properties that affect absorption
and distribution
•  Which toxicokinetic mechanisms govern metabolism and
clearance?
•  What are the key dose metrics?
Child-specific analysis
•  Which age groups should be prioritized for analysis?
•  Utilize various resources to evaluate children’s toxicokinetics:
–  In vivo clearance data from drug literature
–  In vitro enzyme ontogeny data—liver bank studies
–  Developmental physiology literature
–  Animal toxicokinetic data for chemical being analyzed
Choose analytic option and run analysis
•  Quantitative: physiologically based toxicokinetic analysis
•  Semiquantitative: child-specific adjustment factors
•  Qualitative
Toxicokinetic data analysis
•  Do children receive greater internal doses of key dose metric?
•  Characterize variability and uncertainty in children’s toxicokinetics
•  Evaluate whether adult-based risk assessment needs to
be adjusted to account for children’s toxicokinetics
Risk characterization
Figure 1. Outline of toxicokinetic assessment
process for children.characterizing the chemical’s fate and disposi-
tion. Once the major toxicokinetic factors gov-
erning chemical fate are known, then the
approaches that follow can be evaluated for
utility and feasibility.
Use of surrogate chemicals (typically thera-
peutic agents) for which pharmacokinetic data
in children exist. Even if the target chemical(s)
has not been evaluated in children, a chemical
that is similarly processed may have been tested.
Information for surrogate chemicals can help
delineate the maturation of key pathways and
how the target chemical will be handled at cer-
tain developmental stages. This section
describes the kinds of data sets and resources
available for this part of the phase II assessment.
Over the past several years children’s phar-
macokinetic databases have been developed in
which therapeutic drugs tested in both chil-
dren and adults are identified and key
pharmacokinetic parameters are compared
across ages (Ginsberg et al. 2002; Renwick
1998; Renwick et al. 2000). The metabolism
and clearance pathways of many of the drugs
are known, making them useful indicators for
particular pathways. For example, dex-
tromethorphan and debrisoquine are known
substrates for a particular cytochrome P450
(CYP) enzyme, CYP2D6; trimethadione,
chlorzoxazone, and halothane are markers for
CYP2E1 activity; morphine is predominantly
processed by glucuronidation; and a host of
antibiotics are not extensively metabolized but
are mostly excreted unchanged by the kidneys
(Bertz and Granneman 1997; Dollery 2000;
Kurata et al. 1998; Tanaka 1998).
A well-known example of child–adult dif-
ferences in metabolic processing is caffeine, a
process in which an initial N-demethylation
reaction is catalyzed by CYP1A2, and a sec-
ondary N-acetylation step is catalyzed by
N-acetyltransferase (Welfare et al. 2000). The
CYP1A2 reaction is the primary factor govern-
ing the half-life of this drug. Caffeine’s half-life
in newborns is 14-fold higher than in adults,
which is likely the result of the immaturity of
CYP1A2 at this age (Dorne et al. 2001;
Ginsberg et al. 2002; Parsons et al. 1976;
Parsons and Neims 1978). The metabolic
clearance of caffeine and another CYP1A2 sub-
strate, theophylline, becomes more like the
adult rate by 2–6 months of age, after which
time the half-life becomes signiﬁcantly shorter
than in that in adults (Dorne et al. 2001;
Ginsberg et al. 2002). This suggests that once
CYP1A2 function approaches adult levels, the
greater size and blood flow to the liver (per
body weight) in young children can lead to
greater enzymatic clearance of CYP substrates
(Gibbs et al. 1997). However, this also means
that chemicals activated to toxicants by this
pathway [e.g., aromatic amines, polycyclic aro-
matic hydrocarbons (PAHs), aﬂatoxin B1] may
produce more active metabolite in this age
group compared with adults. Unfortunately,
there are no data that can be used to directly
evaluate this possibility.
This drug has also been used to show that
the N-acetyltransferase step is also deﬁcient in
early life. Once caffeine is demethylated by
CYP1A2, it can be N-acetylated to form
5-acetylamino-6-formylamino-3-methyluracil
(AFMU) or excreted in urine in the non-
acetylated form (1-methylxanthine). The ratio
of AFMU to 1-methylxanthine has been used to
phenotype the N-acetyltransferase trait in adults
and children. In children the ratio of acetylated
to nonacetylated metabolite is low in newborns
through 2 months of age (12% of adult ratio),
but then rises to 65% of the adult ratio during
the 2- to 6-month interval (Pariente-Khayat
et al. 1991). This agrees with data showing that
most newborns are slow acetylators but that
beyond 100 days, the underlying genetic poly-
morphism (fast vs. slow) becomes evident (Pons
et al. 1989; Szorady et al. 1987). Such data with
caffeine are examples of the information that
can be obtained from pharmacokinetic data for
therapeutic agents.
Table 1 is a compilation of information
obtained from in vivo pharmacokinetic analy-
ses of drugs with in vitro analyses of enzyme
levels from blood or liver samples. The combi-
nation of the two types of information for a
given clearance pathway can provide a strong
indication of how the pathway’s function
develops in the postnatal period. In vivo phar-
macokinetic data have been analyzed across
chemicals that share a common mode of elimi-
nation in order to develop a more complete
evaluation of the function of speciﬁc pathways
(Ginsberg et al. 2002; Renwick et al. 2000).
Table 1 shows data for six CYP enzymes, sev-
eral phase II conjugation pathways, renal and
biliary clearance, other metabolic functions
(e.g., epoxide hydrolase, alcohol dehydroge-
nase), and two esterases involved in the detoxi-
ﬁcation of organophosphate (OP) pesticides.
This compilation of pharmacokinetic data by
pathway and age group indicates a fairly con-
sistent pattern, that is, premature neonates,
full-term neonates, and infants up to 6 months
of age tend to have less metabolic and clearance
capacity than adults. The two exceptions in the
chart are for enzymes expressed primarily in
the fetal and early postnatal period: CYP3A7
and glutathione S-transferase (GST) pi. These
fetal forms are replaced during the ﬁrst year of
life by corresponding (but not enzymatically
equivalent) adult forms. Beyond 6 months,
many CYP enzymes are sufﬁciently active that
clearance in vivo is actually greater than that in
adults. This appears to be due to the greater
liver size and blood ﬂow in children compared
with adults (Gibbs et al. 1997). Table 1 pro-
vides further evidence for this phenomenon in
that the in vivo data indicate greater clearance
capacity than suggested by the in vitro protein
levels or enzyme activities for CYP1A2,
CYP2E1, CYP2C9/19, CYP2D6, and
CYP3A4, particularly at 6 months of age.
These overall patterns are illustrated for a
speciﬁc CYP, CYP3A4, as evidenced by thera-
peutic drugs that depend upon this CYP for
clearance (Figure 2) (Ginsberg et al. 2002).
CYP3A4 is the major CYP in adult human
liver, but its function is evidently deﬁcient in
early life. This pattern appears to be widely
applicable; an analysis across 40 therapeutic
drugs involving 11 different metabolic/excre-
tory mechanisms shows a similar shift from
immaturity in the earliest age categories to evi-
dence of drug half-lives shorter than adults
beyond 6 months of age (Figure 3).
The period of shorter half-lives in children
relative to adults may represent a time in which
there is faster removal of parent compound but
greater formation of metabolites, which can be
a concern if chemical metabolism leads to
more toxic moieties. However, this may not
lead to greater toxicity if the metabolites are
also cleared more readily in children.
Prediction of the health implications of shifts
in xenobiotic metabolism must be chemical
specific and must consider both parent
compound and toxic metabolites.
The period of accelerated clearance is in
contrast to the earlier periods in which hepatic
metabolism is slower than that in adults, lead-
ing to the potential for prolonged retention and
higher levels of parent compound. This situa-
tion may be compounded by the slower renal
and biliary function at these times. In terms of
detoxification systems, Table 1 shows that
epoxide hydrolase is active at birth but appar-
ently only at 50% of adult function. Although
the data are very limited, it appears that two
forms of GST may be deficient (40–60% of
adult levels) in early life. These data may have
risk implications, given that GSTmu is critical
to epoxide conjugation with glutathione and
that epoxide hydrolase also appears to be slow
in this age group. Thus, the newborn and very
young infant may have a relative deficit in
detoxifying epoxides, although compensating
mechanisms (e.g., other GSTs) may exist. It
should be noted that further research into the
developmental profile of these detoxification
systems is an important research need.
Another potentially important deficit in
children is glucuronidation during the first
2 months of life. Because of the relative deﬁ-
ciency of glucuronide and high bilirubin
levels (an endogenous glucuronidation sub-
strate), it is possible that there will be greater
internal exposure early in life to xenobiotics
(or their metabolites) that require glucuronide
conjugation. This is the case with the anti-
bacterial drug chloramphenicol, in which a
relative lack of glucuronidation contributed
to its accumulation and toxicity (anemia) in
infants (Mulhall et al. 1983; Vest 1965). In
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Table 1. Postnatal developmental proﬁle of pharmacokinetic functions.
Pharmacokinetics Premature Full-term
pathway neonates neonates 1 Week–2 months 2–6 Months 6 Months–1 year 1–2 Years > 2 Years
Renal clearance 35% - in vivo t1/2 28% - in vivo t1/2 88% - in vivo t1/2 137% - in vivo t1/2 137% - in vivo t1/2 185% - in vivo t1/2
for 7 drugsa for 7 drugsa for 7 drugsa for 7 drugsa for 7 drugsa for 7 drugsa
GFR ~20% adultb GFR ~100% adultb
CYP1A1 —c —c —c —c —c —c —c
CYP1A2 2% - PLe 4% - PLe
2% - in vitro EAf 3% - in vitro EAf 16% - PLe 25% - PLe 175% - in vivo t1/2 54% - PLe
11% - in vivo t1/2 4% - in vitro EAg 9% - in vitro EAf 15% - in vitro EAf for 2 drugsa 35% - in vitro EAf
for 2 drugsd 23% - in vivo t1/2 13% - in vitro EAg 13% - in vitro EAg 185% - in vivo t1/2
for 2 drugsd 81% - in vivo t1/2 175% - in vivo t1/2 for 2 drugsd
for 2 drugsd for 2 drugsd
CYP2A6 20% - Nicotine t1/2
ff
CYP2E1 13% - PLh 22% - PLh 30% - PLh 36% - PLh 92% - in vivo serum  82% - PLh
27% - in vitro EAi  39% - in vitro EAI 47% - in vitro EAi 41% - in vitro EAi DMO/TMOc 83% - in vitro EAb
27% - Serum  27% - in vivo serum 97% - Serum 92% - Serum
DMO/TMOj DMO/TMOj DMO/TMOj DMO/TMOc
CYP2C9/19 21% - PLk 30% - in vivo t1/2 29% - PLk 38% - PLk 36% - PLk 36% - PLk 130% - in vivo t1/2
33% - in vitro EAl for 1 drugm 30% - in vitro EAl 45% - in vitro EAl 83% - in vitro EAl 83% - in vitro EAl for 1 drugm
182% - in vivo t1/2 182% - in vivo t1/2
for 1 drugm for 1 drugm
CYP2D6 13% - PLn 22% - PLn 34% - PLn 45% - PLn 88% - PLn
CYP3A4 19% - in vivo t1/2 17% - in vitro EAp 29% - in vitro EAp 37% - in vitro EAp 46% - in vitro EAp 110% - in vitro EAp 189% - in vivo t1/2
for 8 drugso 50% - in vivo t1/2 55% - in vivo t1/2 200% - in vivo t1/2 200% - in vivo t1/2 for 8 drugso
for 8 drugso for 8 drugso for 8 drugso for 8 drugso
CYP3A7 1100% - in vitro EAq 600% - in vitro EAq 300% - in vitro EAq 200% - in vitro EAq
Epoxide hydrolase 42% - PLr 50% - CBZ-E/CBZs 50% - CBZ-E/CBZs 50% - CBZ-E/CBZs 50% - CBZ-E/CBZs 65% - CBZ-E/CBZs
50% - CBZ-E/CBZs
Glucuronidation 23% - in vivo t1/2 34% - in vivo t1/2 47% - in vivo t1/2 102% - in vivo t1/2 84% - in vivo t1/2 84% - in vivo t1/2 74% - in vivo t1/2
for 6 drugst for 6 drugst for 6 drugst for 6 drugst for 6 drugst for 6 drugst for 6 drugst
Sulfation/glucuroni- 84% - APAP clearanceu 149% - APAP  70% - APAP 
dation clearanceu clearanceu
Acetylation 83% slow phenotypev 12% - in vivo caffeine 65% - in vivo caffeine 48% slow
N-acetylationw N-acetylationw phenotypev
GSH transferase GSTαB1 ~ 100% - PLx GSTαB1 ~ 100% - PLx GSTαB1 ~ 100% - PLx GSTαB1 112% -PLx 121% - in vivo t1/2
GSTαB2 ~ 40% - PLx GSTαB2 ~ 40% - PLx GSTαB2 ~ 40% - PLx GSTαB2 62% - PLx of busulfany
GSTmu ~ 60% - PLx GSTmu ~ 60% - PLx GSTmu ~ 60% - PLx GSTmu 93% - PLx
GSTpi >2100% - PLx GSTpi >2100% - PLx GSTpi >2100% - PLx GSTpi 2100% - PLx
Biliary excretion 57% - BSP clearz 70% - BSP clearz 90% - BSP clearz
Serum protein Few binding  Few binding Few binding Increasing # sitesaa Increasing # sitesaa Adult levelaa Adult levelaa
sitesaa sitesaa sitesaa
Serum cholinesterase 50% - EAbb 57% - EAbb 101% - EAbb 91% - EAbb 104% - EAbb
Serum arylesterase 28% - EAcc 34% - EAcc 52% - EAcc 84% - EAcc 80% - EAcc
Alcohol 55%  -  in vivo alcohol 15% - in vitro EAee 32% - in vitro EAee 91% - in vitro EAee
dehydrogenase clearancedd
Abbreviations: APAP, acetaminophen; BSP, bromosulfophthalein; CBZ, carbamazepine; CBZ-E, carbamazepine-epoxide; DMO, dimethadione; EA, enzyme activity; EH, epoxide hydrolase; GFR,
glomerular ﬁltration rate; PL, protein level; TMO, trimethadione.
Pathway function is shown as % adult. aGinsberg et al. (2002) analyzed renally cleared drugs: ampicillin, cimetadine, furosemide, piperacillin, ticarcillin, tobramycin, vancomycin. bGFR in mL/min/kg (Besunder
et al. 1988; Morselli 1989). cCYP1A1 protein or enzyme activity was not detectable in microsomes from liver bank samples at any age, indicating very low constitutive levels (Sonnier and Cresteil 1998).
dGinsberg et al. (2002) analysis of drugs cleared primarily via CYP1A2: caffeine, theophylline. eSonnier and Cresteil (1998) measured CYP1A2 protein levels via immunochemical methods in microsomes from
liver bank samples (n = 6–23 per age group). fSonnier and Cresteil (1998) measured CYP1A2 activity in microsomes from liver bank samples using methoxyresoruﬁn as substrate (n = 6–23 per age group).
gCazeneuve et al. (1994) measured CYP1A2 activity in microsomes from liver bank samples via caffeine N-demethylation. hVieira et al. (1996) measured CYP2E1 protein levels in liver bank microsomes by
immunochemical means (n= 4–23 per age group). iVieira et al. (1996) measured CYP2E1 activity levels in liver bank microsomes using chlorzoxazone as substrate (n= 2 for group 1–10 years of age; otherwise,
n = 9–21 per age group). jTanaka (1998) and Nakamura et al. (1998) report the ratio of oxidized metabolite DMO to parent drug TMO in serum of children dosed at the following ages: < 4 weeks (n = 5);
1m onth–1 year (n = 5); 1–10 years (n = 21); adult (n = 20). CYP2E1 converts TMO to DMO. kTreluyer et al. (1996) measured CYP2C protein levels in microsomal preparations from liver bank samples with
immunochemical techniques. lTreluyer et al. (1996) measured CYP2C19 enzyme activity in microsomal preparations from liver bank samples using diazepam as substrate. mGinsberg et al. (2002) analyzed
tolbutamide, a drug cleared primarily via CYP2C. nTreluyer et al. (1991) measured CYP2D6 protein levels in microsomal preparations from liver bank samples with immunochemical techniques. oGinsberg et al.
(2002) analyzed drugs cleared primarily by CYP3A: alfentanil, carbamazepine, fentanyl, lidocaine, midazolam, nifedipine, quinidine, triazolam. pLaCroix et al. (1997) measured CYP3A4 EA in microsomes from
liver bank samples using testosterone as substrate (n = 12 newborns; 9 at 1 week–1 month; 13 at 1–3 months; 11 at 3–12 months; 2 at > 1 year; 11 adults). qLaCroix et al. (1997) measured CYP3A7 EA in micro-
somes from liver bank samples using dehydroepiandrosterone as substrate (n = 12 newborns; 8 at 1 week–1 month; 20 at 1–3 months; 14 at 3–12 months, 0 at > 1 year; 12 adults). rRatanasavanh et al. (1991)
measured epoxide hydrolase protein levels by Western blot on liver bank microsomal preparations (n =5   for 1 day–1 week of age; n =5for adults). sEH levels were estimated by CBZ-E to CBZ ratio in blood in
different age groups at steady state after repeat drug administration in epileptic patients. Data were pooled across 2 studies (Korinthenberg et al. 1994; Pyonnonen et al. 1977). Higher CBZ-E/CBZ ratios in chil-
dren are indicative of slower EH activity, as CBZ-E formation and CBZ clearance is slower in young children (Eichelbaum et al. 1975, 1985; Kuhnz et al. 1983; Ohmori et al. 1998). tGinsberg et al. (2002) analysis
of drugs cleared directly via glucuronidation: lorazepam, morphine, oxazepam, trichloroethanol, valproic acid, zidovudine. uGinsberg et al. (2002) compilation of kinetic data for APAP across 5 ﬁve studies;
n=7–24 per age group. APAP is a substrate for various conjugation reactions, with sulfation predominating in early life (Besunder et al. 1988; Levy et al. 1975). vPariente-Khayat et al. (1991) measured the ratio
of acetylated to nonacetylated metabolite in urine after caffeine administration in children (n = 10–26). Younger age groups were compared against an older age group (6 months–2 years), as adult data were
not available and onset of rapid phenotype occurs by this age. wSzorady et al. (1987) phenotyped 100 newborns 2–3 days old as well as 100 or more subjects in older age groups, using acetylation of sulfadimi-
dine (as appears in urine). xStrange et al. (1989) measured GST protein levels by radioimmunoassay in liver bank tissue cytosols. GSTαB1 levels were 70% of adult in utero and 112% of adult at 5–10 months
postnatal. Therefore, the estimate is that newborn through 6-month levels would be approximately equal to adult. GSTαB2 protein levels were 25% of adult during the in utero period and 62% of adult at 5–10
months postnatal. Therefore, the estimate is that newborn through 6-month levels are 40% of adult. GSTmu is 22% of adult during in utero period and 93% of adult at 5–10 months. Therefore, the estimate is
that newborn through 6-month levels are 60% of adults. GSTpi is 5300% of adult during in utero period and 2100% of adult at 5–10 months. yGibbs et al. (1997) measured busulfan half-life in a group of 14 chil-
dren (average age = 3 years) relative to adults. Busulfan is metabolized predominately by GSTαB1. zJusko (1972) measured clearance of BSP in groups of 5 or more children; values in young children were
compared against an older child group (3 months–14 years of age), as adult data were not available. aaSerum protein binding sites (albumin, α1-acid glycoprotein) are low in newborns but increase to adult
levels by 1 year (Besunder et al. 1988). bbData were pooled across 4 studies (Augustinsson and Barr 1963; Ecobichon and Stephens 1972; Lehmann et al. 1957; Zsigmond and Downs 1971) in which serum
cholinesterase levels were measured with acetylcholine, benzoylcholine, butyrylcholine, or procaine as substrate. ccAugustinsson and Barr (1963) and Ecobichon and Stephens (1972) measured serum
arylesterase activity with phenyl acetate as substrate. ddIdanpaan-Heikkila et al. (1972) followed the removal of ethanol from mother and newborn blood (n =6   for each age); newborns were exposed
transplacentally and born with equal blood alcohol concentration as mother. eePikkarainen et al. (1967) measured alcohol dehydrogenase activity in liver samples from newborns 1 week–2 months (n = 2);
infants 6 months–2 years (n = 2); older children 5–15 years (n = 3); and adults (n = 3). Data from 9 fetuses were approximately 25% of the newborn levels. ffDempsey et al. (2000) meas-ured nicotine elimination
from newborns (n=5) exposed transplacentally.contrast, some xenobiotics can undergo conju-
gation with alternative cofactors, which allows
a shift in metabolic proﬁle if the primary path-
way is compromised or immature. This occurs
with acetaminophen, where sulfation predomi-
nates early in life until glucuronidation takes
over (Levy et al. 1975).
The ﬁndings described above are consistent
with other pediatric pharmacokinetic summaries
(Dorne et al. 2001; Renwick 1998, 2000) in
which clearance in childhood is slower than in
adults for a variety of drugs and age groups.
There are also cases in which clearance is more
rapid, particularly when the pediatric group was
at least several months of age (Renwick 1998).
This type of age-speciﬁc and pathway-speciﬁc
pharmacokinetics information in children
should prove useful in predicting how children
(particularly neonates) may differ from adults in
internal dosimetry and ultimate risk.
Simply knowing the function of particular
pathways may not be sufficient to predict
in vivo handling of a xenobiotic at a particular
age. Numerous toxicokinetic factors are
involved in chemical processing and clearance,
including partitioning into body compart-
ments, protein binding, respiration, and organ
ﬂows. Therefore, a more comprehensive analy-
sis, such as PBPK modeling, may be needed to
integrate the various factors at work and pre-
dict xenobiotic fate in children. The informa-
tion provided in Table 1, combined with basic
physiologic information, may make PBPK
modeling of children more feasible. Where this
is pursued, the uncertainty and data gaps sur-
rounding input parameters for children must
be recognized and made transparent.
Although characterization of pathway func-
tion on the basis of indicator drugs is a useful
approach, it carries the uncertainty that a drug
may be processed by several clearance pathways.
If one pathway is deﬁcient at a certain age, but
another is more functional, then the overall half-
life or clearance rate may not be affected.
Instead, parent compound may be shunted
from the less active to the more active pathway,
leading to a shift in metabolite profile. The
assignment of chemicals to particular pathways
is based on the fate of the majority (generally
60% or more) of the administered dose in adult
humans, as ascertained from the literature. Shifts
in metabolic processing in early life would tend
to obscure child versus adult clearance differ-
ences based on overall half-life or blood clear-
ance. Thus, in some cases, the data in Table 1
and Figures 2 and 3 may be an underestimate of
the degree of child–adult difference that might
actually exist for a given pathway.
Another caveat for some of the in vivo data
sets cited in Table 1 and Figures 2 and 3 is that
they represent clinical pharmacokinetic trials in
children who are not in full health. The data
sets summarized in Ginsberg et al. (2002) were
screened not only for sufficient numbers of
subjects per age group but also for the health of
the subjects on test. Data for children who
were critically ill or severely compromised,
especially with hepatic or renal conditions that
would affect xenobiotic handling, were
excluded from the database. However, it is pos-
sible that the clinical state of the children being
tested may have affected factors such as volume
of distribution or other pharmacokinetic fac-
tors in certain data sets. The overall concor-
dance between in vitro and in vivo data shown
in Table 1 suggests that this factor is not a
systematic issue here.
Use of in vitro data to ascertain how toxi-
cokinetic pathways change during develop-
ment. The liver bank data describing CYP
protein levels and enzyme activities, as well as
the serum esterase data shown in Table 1, can
be used as indicators of pathway function at
particular ages. These data are made more
reliable for risk assessment when there are
corroborating in vivo half-life or clearance data
for indicator chemicals. An example is CYP2E1
function, in which in vitro liver bank studies
(Figure 4A,B) generally agree with in vivo drug
metabolism data for the CYP2E1 substrate
trimethadione (Figure 5) (Nakamura et al.
1998; Tanaka 1998; Vieira et al. 1996). These
developmental proﬁles can be essential for esti-
mating the degree to which CYP2E1-mediated
metabolic activation may occur for a wide vari-
ety of environmental toxicants (e.g., benzene,
chlorinated solvents, ethanol).
Use of developmental information to eval-
uate how toxicokinetics can affect susceptibility
during the in utero period. The maternal–fetal
environment presents unique toxicokinetic con-
siderations. The developing organism is
exposed as part of the maternal system via pla-
cental transport. Although maternal factors
(distribution, metabolism, excretion) govern
fetal exposure, exposure to the fetus can be
quantitatively or qualitatively different from
that in the mother. This may result from chem-
ical accumulation in the fetal compartment
(NRC (National Research Council) 2000) or
from in situ metabolism that causes fetal expo-
sure to metabolites different from that experi-
enced in the maternal system. The following
sections are a summary of the key toxicokinetic
factors during in utero development.
Placental transport. Between the maternal
system and conceptus is a specialized set of
membranes that chemicals must cross. The
placenta has its origins in the conceptus, with
its unique anatomical and functional features
inﬂuencing chemical transfer to the develop-
ing conceptus. This set of membranes under-
goes considerable change with development
and also exhibits substantial species differ-
ences. As pregnancy progresses, there is closer
contact between the fetal blood and the syncy-
tiotrophoblast—the placental cell layer most
important to placental function and mater-
nal–embryo/fetal exchange (Garbis-Berkvens
and Peters 1987). This leads to greater
exchange of nutrients and chemicals across the
placenta as gestation proceeds. On the macro-
scopic level, the effects of gestational age can
be exempliﬁed by comparing the tremendous
change in the ratio of placental/fetal weight
(ratio equals 4 at 10 weeks and 0.2 at
40 weeks) (Hytten and Leitch 1971).
Any substance in the maternal circulation
can be transferred, to some exent, across the
placenta unless it is metabolized/eliminated
before or during its placental passage (Garbis-
Berkvens and Peters 1987; Slikker 1987). A
useful method for characterizing placental
transfer across chemicals and species is the
dually perfused placenta. This is an in vitro
preparation in which placental transfer is
defined as a clearance ratio. Studies of non-
metabolized model compounds indicate
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Figure 2. Analysis of children’s pharmacokinetic
database half-life results for CYP3A substrates—
alfentanil, carbamazepine, fentanyl, lignocaine,
midazolam, nifedipine, quinidine, and triazolam.
Child/adult half-life ratios were derived by a com-
posite analysis of the eight CYP3A drug substrates
in the children’s pharmacokinetic database. Data
were organized into age categories shown. Figure
reproduced from Ginsberg et al. (2002) with permis-
sion from Oxford University Press. 
*p< 0.1; **p< 0.05. 
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Figure 3. Analysis of children’s pharmacokinetic
database: half-life results for full database—
40 substrates. Child/adult half-life ratios were
derived by a composite analysis of the 40 drug sub-
strates in the children’s pharmacokinetic database
containing half-life results. Data were organized
into age categories shown. Figure reproduced from
Ginsberg et al. (2002) with permission from Oxford
University Press.
**p < 0.01; ***p< 0.001. decreases in placental transfer as the molecu-
lar weight of the model compounds increases
(Illsley et al. 1985). Under these very con-
trolled conditions without maternal or fetal
involvement, differences in placental transfer
between species are evident, with sheep being
more different than guinea pig from human.
These types of functional assessments help to
predict placental transfer and fetal exposure
after maternal dosing.
Additional factors that inﬂuence the placen-
tal transfer of chemicals are uterine/placental
blood ﬂow, placental permeability, and placen-
tal metabolism (Juchau 1980a, 1980b; Mihaly
and Morgan 1983; Miller et al. 1976; Mirkin
and Singh 1976; Waddell and Marlowe 1981).
These factors are not static during pregnancy
but may change as gestation progresses. 
Chemical delivery to the developing con-
ceptus relies primarily on blood flow to the
placenta. Although chemicals may transfer
from mother to fetus via the amniotic fluid
after crossing the amnion, the majority of
agents gain access to the conceptus via placen-
tal passage (Nau and Liddiard 1978). In
addition to the changes in placental blood ﬂow
that occur during gestation, changes in blood
ﬂow as a result of chemical exposure must also
be considered. Although experimentally
induced changes in placental blood flow can
alter normal development of the conceptus
(Barr and Brent 1978; Greiss and Gobble
1967; Millicovsky and DeSesso 1980), the
effect of such perturbations on placental trans-
port of xenobiotics needs to be evaluated.
Placental permeability to a chemical is
influenced both by placental characteristics
(e.g., thickness, surface area, carrier systems,
and lipid/protein content of the membranes)
and also by characteristics of the chemical
agent (e.g., degree of ionization, lipid solubil-
ity, protein binding, and molecular weight)
(Mihaly and Morgan 1983; Mirkin and
Singh 1976; Welsch 1982). The rate of pla-
cental transfer is rapid for nonionized, lipid-
soluble chemicals of low molecular weight
(less than 1,000 daltons) and is largely con-
trolled by placental blood flow (Mihaly and
Morgan 1983; Mirkin and Singh 1976).
However, charged molecules such as tubocu-
rarine can also enter the fetus (Kivalo and
Saarikoski 1972, 1976). Similarily, chemicals
highly ionized at normal blood pH, such as
the salicylates, readily cross the placenta
(Wilson et al. 1977). The question is thus not
whether a compound crosses the placenta but
rather at what rate.
Maternal considerations. A chemical must
pass through and may interact with several
anatomical compartments on its journey from
the site of maternal exposure to the organ sys-
tems of the developing conceptus. Maternal
factors act to either enhance or diminish the
concentration of an active chemical in the
conceptus. Maternal detoxification decreases
the amount of parent compound available for
placental transport, whereas maternal bioacti-
vation may make more active chemical avail-
able. The entire set of maternal toxicokinetic
factors (e.g., absorption, distribution, serum
binding, and elimination) also inﬂuences the
concentration of active agent at the target site.
Because of the physiologic changes that occur
during pregnancy, the influence of these
maternal factors on chemical delivery may also
change during gestation (Bogaert and Thiery
1983; Cummings 1983; Juchau 1995; Juchau
and Faustman-Watts 1983; Noschel et al.
1980). These issues have been reviewed
(Brock-Utne et al. 1980; Juchau and
Faustman-Watts 1983; Krauer et al. 1980;
Levy 1981; Slikker and Miller 1994).
For chemicals that bind avidly to plasma
proteins, this factor can retard placental trans-
fer. In general, only the free drug crosses the
membranes of the placenta (Krauer et al. 1980;
Welsch 1982). Protein binding is usually
reversible, and there are a finite number of
binding sites. Thus, binding is saturable, and
equilibrium may be described by the law of
mass action (Krauer et al. 1980; Miller et al.
1976). As long as binding is reversible, it does
not prevent the chemical from crossing mem-
branes but only slows the rate at which the
transfer occurs (Levine 1973).
Placental biotransformation. This may be
the most critical factor in influencing the
delivery of chemicals to the developing con-
ceptus. Placental biotransformation of a chem-
ical prior to fetal delivery may dramatically
alter the chemical profile in the conceptus
from that in the mother (Slikker et al. 1982).
Equilibrium factors, which inﬂuence the rate
of placental transfer, can result in quantitative
differences of exposure. Placental metabolism,
however, can qualitatively alter the exposure of
the conceptus to potentially toxic chemicals.
Placental metabolism is less well characterized
than hepatic metabolism, but existing data
suggest that the placenta has considerably less
metabolic capacity than adult liver (Juchau
1980b; Mirkin and Singh 1976). A listing of
some of the human placental xenobiotic and
hormone-metabolizing enzymes or isoenzymes
is presented in Table 2.
Embryo/fetal considerations. As with
most organ systems, the various chemical-
metabolizing systems undergo quantitative if
not qualitative changes during development.
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Figure 4. (A) Age-related variations of CYP2E1 protein in the human liver. Microsomal proteins (60 µg) were
separated on a 9% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to nylon mem-
branes. CYP2E1 was immunochemically detected with a polyclonal antibody raised against rat ortholog
CYP2E1; the antigen–antibody complex was visualized after addition of peroxidase-conjugated anti-(rabbit
IgG) antibody using 4-chloro-1-naphthol as the dye and quantiﬁed by scanning with an image analysis system.
Results are expressed as the mean ± SE of densitometric values of immunochemically detected CYP2E1 per
milligram protein. Optical density (OD) units are an arbitrary measure of the density. Number per group is indi-
cated between brackets. (B) Age-related variations of chlorzoxazone hydroxylation in human liver.
Microsomal samples (0.3 nmol P450) were incubated with 500 µM chlorzoxazone and an NADPH-generating
system. The formation of the 6-hydroxylated metabolite was monitored at 287 nm after separation by high per-
formance liquid chromatography. Results are expressed as the mean ± SE of activity measured as rate of for-
mation of 6-hydroxychlorzoxazone per mg microsomal protein. Number of samples in each group is indicated
between parentheses. Figure reproduced from Vieira et al. (1996) with permission from Blackwell Publishing. 
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Figure 5. Age-related changes over seven stages of
life in the serum dimethadione (DMO)/trimethadione
(TMO) ratio 4 hr after oral administration of TMO
(4 mg/kg). The seven stages were neonates
(< 4 weeks, n = 5), infants (< 12 months, n = 12), chil-
dren (< 10 years, n = 21), adolescents (< 20 years,
n=3), young adults (< 40 years, n= 20), mature adults
(< 65 years, n = 20), and elderly adults (> 65 years,
n = 40). Mean ± SE. Figure reproduced from Tanaka
(1998) with permission from Blackwell Publishing.Chemical biotransformation by the developing
conceptus has been extensively reviewed
(Dutton 1978; Dutton and Leakey 1981;
Dvorchik 1981; Eltom et al. 1993; Juchau and
Faustman-Watts 1983; Leakey 1983; Nau and
Neubert 1978; Neims et al. 1976; Pelkonen
1977, 1980; Rane and Tomson 1980; Slikker
1987, 1994; Slikker and Miller 1994). Despite
that data have been collected using a variety of
techniques and some data gaps exist because of
technical or ethical reasons, several general
conclusions may be drawn from the literature.
• During prenatal development, the activities
of most enzymes that catalyze phases I and II
reactions are lower than those in adults.
• As in the adult, the conceptus exhibits
substrate speciﬁcity in its ability to metabo-
lize chemicals, suggesting the existence of sev-
eral sets of enzymes or isozymes, which may
or may not be the same as those in the adult.
• These enzyme systems may be inhibited or
induced by maternal pretreatment with a
variety of chemicals.
• Enzyme activity generally increases with
gestational age.
• The ontogeny of each enzyme may be differ-
ent, and the controlling mechanisms of mat-
uration of enzyme activity are incompletely
understood.
• Prenatal human and nonhuman primates
exhibit higher levels of many metabolizing
enzymes (especially P450s) than do com-
monly used laboratory species.
• As in the adult, the liver of the conceptus
appears to have the greatest capacity for
chemical metabolism. The fetal adrenal,
kidney, lung and brain also exhibit metabolic
capabilities.
Table 3 summarizes recent data concerning
some CYP isozymes and their occurrence in
human fetal tissues.
Fetal distribution and elimination. The
majority of chemicals entering the fetal
circulation do so via the umbilical vein after
passage through the placenta. A portion of the
blood ﬂow entering the liver of the conceptus
is shunted via the ductus venosus directly to
the inferior vena cava and to the heart for total
body distribution (Rudolph and Heymann
1967). The remaining umbilical flow enters
hepatic tissue and exits to the vena cava via the
portal vein (Dawes 1968). There is potential
for a signiﬁcant ﬁrst-pass effect from chemical
passing through the fetal liver prior to other
sites; however, a substantial fraction passes
directly to the remaining tissues (Power and
Longo 1975). As in the adult, approximately
16% of the fetal cardiac output is directed
toward the fetal brain (Behrman et al. 1970).
Just as placental transfer of chemicals is the
predominate pathway from the maternal sys-
tem to the conceptus, placental transfer is also
the predominate route for embryo/fetal elimi-
nation of chemicals. The same toxicokinetic
rules apply for fetal-to-maternal transport
across the placenta: chemicals that are nonion-
ized and lipid soluble will diffuse across the
placenta according to the concentration gradi-
ent from conceptus to mother. However, if a
chemical has been conjugated by the fetus
(e.g., glucuronidation, sulfation) or otherwise
metabolized to a more polar form, the rate of
return to the maternal circulation will be
slower than that for the parent compound
(Dancis et al. 1958; Goebelsmann et al. 1968,
1972; Levitz et al. 1960). PBPK models to
predict the fate of toxicants in fetal tissues as a
function of development are emerging (Kim
et al. 1996; Sandberg et al. 1996).
Use of animal toxicokinetic information to
evaluate how development can affect internal
dosimetry. Laboratory animals can be useful in
a number of respects in providing toxicokinetic
data and related information for children’s risk
assessments of environmental pollutants
(Harroff et al. 1997). The discussion here will
be limited primarily to mice and rats, as most
toxicokinetic and toxicology studies employ
these two rodent species.
Diversity is one of the more daunting
problems anticipated when studying children
because of the numerous variability factors
described earlier. Intersubject variability is
substantially lower in homogeneous rodent
populations provided by major animal suppli-
ers. Uniform groups of animals of the same
established genetic and husbandry backgrounds
can be maintained under deﬁned and carefully
controlled conditions. Therefore, it is possible
with animal studies to control more variables
and to better focus on age-dependent differ-
ences in chemical metabolism and disposition.
Animal toxicokinetics and susceptibility
to xenobiotics. Series of studies of OPs in rats
have clearly shown that the relatively low
detoxification capacity of weanlings places
them at increased risk of acute, high-dose OP
poisoning. Benke and Murphy (1975) con-
cluded that the lower acute toxicity of
parathion and methyl parathion in adult rats
was due to the adults’ greater detoxification
capacity. More recent studies have conﬁrmed
and extended these ﬁndings. The maturational
proﬁles of P450-catalyzed desulfuration (acti-
vation) and dearylation (inactivation) as well
as carboxylesterase and arylesterase (inactiva-
tion) activities have been characterized in the
liver and/or blood of rats (Atterberry et al.
1997; Moser et al. 1998). Despite very low
carboxylesterase and arylesterase activities, rat
fetuses and sucklings appear to be protected
from chlorpyrifos because of limited transfer
of the compound from the mother (Mattsson
et al. 2000). However, this protective effect
would not be expected if neonates were
exposed directly (i.e., not via the mother) to
OPs. On the basis of somewhat anecdotal
information of groups of people poisoned by
these pesticides, the suggestion is that young
Mini-Monograph | Ginsberg et al.
278 VOLUME 112 | NUMBER 2 | February 2004 • Environmental Health Perspectives
Table 2. Partial list of human placental xenobiotic- and hormone-metabolizing enzymes or isoenzymes.a
Phase Type Reaction (gene) Substrate Constitutive Inducer Inhibitor
I MFO O-Deethylase (CYP1A1) 7-Ethoxycoumarin (+) Cigarette smoke Aminoglutethimide
I MFO Aryl hydrocarbon hydroxylase (CYP1A1) PAH (?) Cigarette smoke Alpha-naphthoﬂavone
I MFO Hydroxylase (CYP3A7) Cortisol + _ _
I MFO Aromatase (CYP19) Androgens (+) _ Aminoglutethimide
I MFO Cholesterol side-chain cleavage (CYP11A) Cholesterol (+) _ Aminoglutethimide
I MFO Estrogen catechol formation,  Estrogens (+) Cigarette smoke _
2-Hydroxylation (CYP1A1)
4-Hydroxylation (CYP1B1)
I MFO 25-Hydroxycholecalciferol hydroxylase 25-Hydroxycholecalciferol _ _
I Oxidoreductase 17β-Hydroxydehydrogenase (+) _ 16-Methylene estradiol
Type 1 Estrone to estradiol
Type 2 Estradiol to estrone
I Oxidoreductase 11β-Hydroxydehydrogenase Cortisol/cortisone (+) _ _
I Oxidation Dehydrogenase Alcohol/acetaldehyde (+) _ _
I Oxidation Monoamine Norepinephrine (+) _ Monoamine oxidase inhibitors
II Sulfatase Sulfate cleavage Steroid sulfates (+) _ _
II Conjugation GST Epoxides (+) _ _
II Conjugation Catechol-O-methyltransferase Catecholamines, catechol estrogens (+) _ _
Abbreviations: MFO, mixed-function oxidase; (+), the enzyme is constitutively expressed in human placenta; (?), it is unclear whether the enzyme is constitutively expressed; –, no known
inducer or inhibitor for the placental enzyme. aData modiﬁed from Slikker and Miller (1994), with additional data from Arcuri et al. (1999); Juchau (1995); Moghrabi et al. (1997); Rasheed
et al. (1997); and Zusterzeel et al. (1999).children (0–4 years of age) are at increased risk
(Diggory et al. 1977; Zwiener and Ginsburg
1988). However, the exposure information is
not detailed suffciently in these cases to con-
ﬁrm the sensitivity of any particular person or
age group. Ecobichon and Stephens (1972)
reported that blood arylesterase activity is rela-
tively low in young children (1–2 years of
age), with this group having pronounced
intersubject variability. No more recent infor-
mation could be located on the time course of
maturation of arylesterase or related enzymes
in human blood or liver.
Comparative studies show that neonatal
rodents are frequently more susceptible to toxi-
cants than adult animals, but such findings
should be interpreted with caution when
extrapolating to humans. Done (1964) and
Goldenthal (1971) compiled the results of
LD50 (median lethal dose) studies of several
hundred chemicals in neonatal and mature
rodents. The neonatal animals were more sen-
sitive to many but not all the compounds.
Almost all the age-dependent differences in
LD50 values were less than an order of magni-
tude; indeed, most varied no more than 2- to
3-fold. More pronounced interage differences
were seen for a few drugs, some of which (e.g.,
chloramphenicol, diazepam) are poorly
metabolized and accumulate to toxic levels in
human newborns. As full-term human new-
borns are more mature than their rodent coun-
terparts with respect to liver metabolism,
interage differences might be less pronounced
in humans. However, maturation is much
more rapid in rodents, such that even a few
days of growth can result in marked disparity
in chemical metabolism, disposition, and
effects. Results from the Done (1964) acute
toxicity compilation (Figure 6) suggest dra-
matic differences in sensitivity in early post-
natal life. These types of examples from the
animal literature may be excellent research
opportunities for exploring the relative impor-
tance of toxicokinetic versus toxicodynamic
mechanisms in determining susceptibility in
early life. Although the animal research may be
able to point out mechanisms of toxicokinetic
susceptibility, extrapolation of temporal trends
across species is difficult because organs and
their associated functions mature at different
rates in different species. This makes the choice
of an appropriate animal model for children
complex and cross-species extrapolations more
uncertain than what we are accustomed to in
adult risk assessments [Bruckner 2000; NAS
(National Academy of Sciences) 1993].
Despite the dissimilarities in maturation
mentioned previously, rodent studies can pro-
vide valuable information on mechanisms and
specific immaturities that may be broadly
applicable to infants and children. Heavy met-
als are a good example. It is widely recognized
that dietary antigens, maternal antibodies, and
other macromolecules may be absorbed
through the immature gastrointestinal mucosa.
Increased levels of relatively polar molecules in
the cerebrospinal ﬂuid of infants suggest that
such compounds penetrate the blood–brain or
blood–cerebral spinal ﬂuid barrier more readily
in infants than in children and adults (Adinolﬁ
1985; Dziegielewska et al. 2000). Therefore, it
has been hypothesized that equivalent expo-
sures of infants and adults to heavy metals such
as mercury and lead will result in greater oral
absorption and greater central nervous system
deposition (and toxicity) in the infants. Kostial
et al. (1978) demonstrated substantially greater
gastrointestinal absorption and whole-body
retention of lead, mercury, and cadmium by
suckling rats than by adults. A similar phe-
nomenon has been reported for lead in juvenile
monkeys (Pounds et al. 1978) and human
infants (Ziegler et al. 1978). Retention of intra-
venously injected lead was 8 times higher in
the brains of suckling rats than in the brains of
adults (Kostial et al. 1978). Brain retention of
injected mercury was 19 times higher during
the perinatal period. Rodents have been very
useful in delineation of the toxicokinetic basis
of age-dependent differences in heavy-metal
toxicity, but subhuman primates are generally
the animals of choice to examine toxico-
dynamic factors (Davis et al. 1990).
Relatively few in vivo data are available
from kinetics studies of drugs or other chem-
icals in preadolescent animals because of
technical difficulties in working with such
small subjects and prior lack of interest in
immature populations. Similarly, there is a
paucity of information on the maturation of
many physiologic processes in small animals.
The maturation of hepatic xenobiotic metabo-
lism in rats, in contrast, has been relatively well
characterized (Imaoka et al. 1991; Renwick
1998; Watanabe et al. 1993). Although rat
liver is immature at birth with respect to many
metabolic functions, certain CYP functions,
epoxide hydrolase, and glucuronidation func-
tion reach adult levels within the ﬁrst week to
10 days. Other functions such as glutathione
transferase and aryl hydrocarbon hydroxylase
take longer to develop (Renwick 1998).
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Figure 6. Changes in chemical susceptibility with age. Figure adapted from Done (1964). 
Table 3. Some CYP isozymes and their occurrence
in human tissues.a
Adult Adult Fetal Fetal 
CYP liverb brainb liverb brainb
1A1 + + +
1A2 +++ – –
1B1 + + +
2A6 ++ –
2A7 + –
2B1/2B2 + +
2B6/2B7 + –
2C +++ ±
2C8-19 + + +
2D6 + + ±
2E1 + + ±
2F1 – –
3A4 +++ + ±
3A5 ++ +
3A7 + +++
4B1 – –
aData modified from Carpenter et al. (1997); Chen et al.
(1999); Farin and Omiecinski (1993); Hakkola et al. (1994,
1997, 1998a, 1995b); LaCroix et al. (1997); Maenpaa et al.
(1993); Murray et al. (1992); Ravindranath and Boyd (1995);
Slikker (1997); and Yang et al. (1995). b±, possibly present in
small quantities, or mRNA observed but no protein conﬁr-
mation; –, not detected; +, present in low levels; ++, pre-
sent in moderate levels; +++, present in high levels.Despite these known metabolic differences
during development, ﬁndings of increased sus-
ceptibility in juvenile rodents have not been fol-
lowed up to determine whether toxicokinetic
mechanisms underlie these susceptibility differ-
ences. For example, Yoo et al. (1987) observed
that CYP2E1-catalyzed metabolic activation of
N-nitrosodimethylamine to a mutagen was sub-
stantially greater by hepatic microsomes of
weanlings (25 days of age) than those of adult
rats. Carbon tetrachloride, a chemical that also
undergoes CYP2E1-catalyzed metabolic activa-
tion, was more hepatotoxic in 15-day-old than
in 60-day-old male rats (Jahn et al. 1993).
However, no accounts were located of animal
studies relating susceptibility to injury by these
CYP2E1 substrates to the time course of matu-
rational changes in the chemical’s metabolism.
Data gaps and challenges in applying ani-
mal data to children’s toxicokinetic assess-
ments. It is possible, under certain well-deﬁned
conditions, to make reasonable predictions of
the disposition of drugs in adult humans on
the basis of animal studies (Lin 1995). For
example, the oral absorption of lipophilic com-
pounds is relatively species independent, as is
the volume of distribution of unbound drug
(Fichtl et al. 1991; Lin 1995). Methods to
extrapolate other parameters such as renal
excretion of ﬁltered drugs across species pro-
vide reasonable estimates for human pharma-
cokinetic function (Lin 1995). However,
across species, differences in protein binding
and drug metabolism can be substantial, lead-
ing to greater uncertainty in relying on
pharmacokinetic data generated in animals
(Nedelcheva and Gut 1994; Stevens et al.
1993). Nevertheless, metabolic clearance of
low doses of ﬂow-limited drugs should be less
dependent on species-inherent rates of metabo-
lism than on relative liver blood ﬂow rates (Lin
1995). Thus, data from animal studies often
can be useful in forecasting toxicokinetics in
humans when their limitations are considered.
However, this conclusion is based on compari-
son of adult animals with human adults. The
development of toxicokinetic functions in early
life is sufﬁciently different in rodents compared
with humans to make direct extrapolation
from juvenile animal studies difﬁcult.
As mentioned above, one of the most
promising approaches to quantitative estima-
tion of internal doses of chemicals in children
is PBPK modeling. Models have been devel-
oped to describe the disposition of a number of
chemicals in pregnant rodents and their fetuses
as well as in the lactating rat and nursing pup
(Krishnan and Andersen 1998). Luecke et al.
(1994) and Welsch et al. (1995) have adapted
such models to human pregnancy to forecast
potential teratogenic events. O’Flaherty devel-
oped PBPK models that accurately predicted
time courses of lead in the blood and its depo-
sition in bones of developing rats (O’Flaherty
1991) and children (O’Flaherty 1995). These
models incorporated age-dependent changes in
body weight, tissue volumes and blood ﬂows,
and bone formation and resorption rates.
Pelekis et al. (2001) have made assumptions
about distributions of physiologic and bio-
chemical parameters in children and have esti-
mated their effects on the disposition of
volatile organic chemicals. Gentry et al. (2002)
have modeled a variety of different chemicals
across a wide range of ages by building func-
tions into their model that adjust for metabo-
lism and renal function changes during
development.
Knowledge gained from PBPK modeling
efforts with animals can be of signiﬁcant beneﬁt
in the understanding of the kinetic behavior of
chemicals in humans and in developing PBPK
models for humans. Toxicokinetic studies in
animals can yield a number of important para-
meters, including in vivo and in vitro partition
coefﬁcients, metabolic rate constants, and iden-
tity and stoichiometric yield of metabolites.
Such chemical- and species-specific data are
needed to construct an appropriate model. The
model may be used to generate simulations of
the time course of parent compound and/or
metabolite(s) in blood, tissues, and urine. This
information is often useful in design of the
in vivo kinetics experiments needed to assess the
accuracy of the model’s predictions. When
physiologic parameters are scaled allometrically
to humans, the animal-based model becomes a
starting point for making predictions regarding
human pharmacokinetics. However, develop-
ment of PBPK models for children would
require extra effort to scale the model to the
physiology and functional immaturity that
occurs at specific developmental stages.
Although it is tempting to use juvenile animal
data to inform such children’s PBPK modeling
efforts, the across-species differences in physio-
logic and biochemical maturation add substan-
tial uncertainty to this approach. Data in
juvenile subhuman primates may be more
promising because of their similarity to growing
children (Conrad et al. 1995), but this would
involve more expense. 
Use of basic physiologic differences across
age groups to ascertain how factors such as
renal clearance, protein binding, and lipid par-
titioning may vary with age. Renal clearance
and protein binding capacity are immature at
early postnatal stages and develop over the
course of the first 6 months to year of life
(Table 1). Glomerular ﬁltration rate as well as
transporter (secretory) systems in the proximal
convoluted tubule are deﬁcient at birth (Kearns
and Reed 1989; Morselli 1989), leading to rela-
tively slow clearance of a wide array of antibi-
otics and other renally cleared drugs and
metabolites. Compounding the chances for
greater chemical effect in the ﬁrst months of life
is a deficient protein binding status due to
lower levels of albumin (which binds weakly
acidic chemicals) and alpha-1-glycoprotein
(which binds basic chemicals). Another issue is
the relative deﬁciency to conjugate and excrete
bilirubin early in life, which leads to greater
occupation of serum binding sites by bilirubin.
These factors may contribute to a greater ratio
of free compared with bound chemical, leading
to a higher potential for uptake into tissues and
toxic action. Diminished protein binding can
also lead to shorter duration of action because
of greater availability of chemical for metabo-
lism and elimination. These factors would
likely be important only for chemicals that
exhibit a high degree of plasma protein binding
(e.g., trichloroacetic acid).
Summary of phase II toxicokinetic analy-
sis. As information in the areas described
above is gathered and processed, we can evalu-
ate from an internal dose perspective which
age group(s) appears to be most exposed. Age
groups that appear to differ most from adults
can be prioritized for more detailed analysis as
the process continues. The following questions
may be helpful:
Does the pharmacokinetic proﬁle shift at
natural age breakpoints? An early step in ana-
lyzing children’s toxicokinetic data is deciding
whether and how to create bins across ages. The
rapid development of children requires that the
population be broken into relatively small age
groups, particularly in the early postnatal
period. If larger bins are used, the data may
become highly variable, with age specificity
becoming a causality of the desire to simplify
the assessment. Thus, bins must be constrained
to reﬂect key developmental stages. Neverthe-
less, it is useful to make them as large as possi-
ble, as this maximizes the number of subjects
per group and enhances the power of cross-age
comparisons. It should be noted that similar age
binning may occur in the exposure and toxico-
dynamic areas to reflect critical changes in
behavior or windows of heightened vulnerabil-
ity. At some point the children’s kineticist may
be asked to adjust his bins to match those cre-
ated in these other areas for the sake of harmony
and to allow risk calculations for neatly deﬁned
age groups. Age bins were developed to organize
the data shown in Table 1 and Figures 2 and 3.
These bins are somewhat arbitrary and were
based on the overall availability of data for a
variety of pathways and chemicals. For speciﬁc
chemicals and pathways, alternative bins can
certainly be considered.
Which pharmacokinetic parameters are
most important in determining internal dose?
Although PBPK models aim for the simplest
approach that yields predictive results, there are
inevitably many parameters that must be esti-
mated to run the model. These parameters
include compartment size, partition coeffi-
cients, cardiac output, organ blood flows,
metabolic rates, lung ventilation rates, and
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contain multiple tissue compartments and we
may be dealing with several different age
groups, there is a potentially large number of
parameter values that would require elucida-
tion. However, the model may not be equally
sensitive to all the inputs, making those para-
meters that have the greatest influence on
model performance the most important to cali-
brate properly. Efforts to simplify pharmaco-
kinetic modeling in both adults and children
have relied on a series of algebraic equations
that highlight key pharmacokinetic parameters
while not including others that may be model
insensitive (Pelekis et al. 2001). Such approaches
point out the importance of identifying those
pharmacokinetic parameters that drive internal
dose. Which pharmacokinetic factors are most
inﬂuential will depend on the properties of the
chemical under investigation. The clearance of
chemicals with high hepatic extraction (rapid
liver metabolism) will depend primarily on
hepatic blood flow, whereas chemicals with
low hepatic extraction depend most on the rate
of liver metabolism relative to other competing
rates (urinary elimination or exhalation of par-
ent compound). To determine the focus of a
children’s toxicokinetic analysis, the most
important toxicokinetic parameters in a vali-
dated adult model must be determined.
Additional effort can then be put into identify-
ing how these parameters change as different
child age groups are considered. Ultimately,
the fate of any chemical will be determined by
the interaction of all pharmacokinetic factors
acting simultaneously. This kind of sensitivity
analysis will ensure that those parameters with
the greatest inﬂuence are given the attention
they warrant. 
Regardless of whether one is conducting a
full PBPK assessment across ages or a less rig-
orous approach, it is important to know how
key parameters change with age. As discussed
above, various data resources and analytic
approaches may be used to determine how key
parameter values differ between children and
adults. Similar to Table 1, it may be helpful to
develop a table of key physiologic and meta-
bolic parameters that affect the fate of the
chemical in question and list what is known
about those pathways for the in utero and
postnatal periods. If the parameter values are
not materially different between children and
adults or if it appears that certain factors
negate one another, one might conclude that
it is not important to conduct further toxico-
kinetic assessment for that age groups(s).
However, for those chemicals and age groups
where children appear to receive a greater
internal dose of active toxicant, further
analytic steps may be considered as follows:
Semiquantitative approaches. Investigators
should use information on the predominant
disposition pathways to evaluate child/adult
dosimetry differences. It may be possible to
base conclusions on one or more particularly
useful surrogates from the drug literature. In
cases where pathways that govern chemical
activation or clearance appear to be substan-
tially different across early life and adults, an
age group–speciﬁc adjustment factor may be
considered. This may be based on the size of
the child/adult ratio in that parameter value,
using comparisons based on central tendency
values or on bounding percentile in children
versus central tendency in adults (e.g., 5th per-
centile of child metabolic function vs. adult
median percentile). Such adjustment factors
provide the opportunity for the risk assessment
to consider child-speciﬁc toxicokinetic infor-
mation readily available. However, it is a sim-
plistic approach that does not consider the
various ways in which changes in one path-
way’s function may be modiﬁed by other phys-
iologic factors, leading to an overall inﬂuence
greater or less than expected. A more complete
analysis involving PBPK modeling is needed to
integrate child/adult differences in a variety of
parameters into across age-group comparisons
of internal dosimetry.
Quantitative approaches—PBPK analysis.
This involves constructing a child age
group–specific model that incorporates the
base physiologic parameter values specific to
the age group(s) being analyzed as well as mod-
iﬁcations in metabolism and renal clearance to
reflect the major functional immaturities in
early life. This model would then incorporate
chemical-speciﬁc parameter values to simulate
how children at speciﬁc developmental stages
are likely to handle the chemical. It is essential
to carefully consider data needs for such an
analysis and whether sufﬁcient data exist or can
be generated/estimated.
Ideally, phase II of the children’s toxicoki-
netic risk assessment would result in the
following:
• An understanding of the toxicokinetic mech-
anisms that govern the fate of the target
chemical
• Data resources that describe how these mecha-
nisms change during development
• An initial prioritization of age groups for more
detailed analysis based on likelihood for inter-
nal dosimetry differences relative to adults
• An analytic strategy (semiquantitative or
quantitative techniques) for incorporating
these data into the risk assessment process.
Phase III: Risk Characterization
The analytic approaches developed in phase II
would be followed through so that phase III
can attempt to answer the following questions:
• How similar/dissimilar are in utero and child-
hood stages to adults in terms of internal
dose received per unit of administered dose?
• How variable are young age groups versus
adults?
• Do all age groups fall within the default
interindividual variability factor of 3.2?
• Do child:adult differences warrant the devel-
opment of chemical- and age-speciﬁc uncer-
tainty factors?
• Can internal dosimetry estimates for different
age groups be developed and used in quanti-
tative risk assessment?
To place the analytical results in perspec-
tive, the risk characterization will usually try to
describe the degree of uncertainty and variabil-
ity in the analysis. The following questions may
be particularly pertinent to such a discussion.
Are children more variable in their phar-
macokinetic responses than adults? How do we
assess and apply this information? The role of
variability in the risk assessment process can
range from purely qualitatitive (e.g., people are
different from one another, so we are not as
certain as we would like to be about the degree
of risk) to semiquantitative (e.g., people vary
considerably in metabolizing chemical X, so it
seems prudent to use a half-log toxicokinetic
uncertainty factor) to fully quantitative (e.g.,
we have sufﬁcient individual data to plot the
population distribution of effective internal
doses per unit of external dose, so let us show
the risk manager the cleanup options that pro-
tect the 50th, 75th, 90th, and 95th per-
centiles). The fully quantitative mode of
variability analysis is used in lead uptake/bioki-
netic modeling to enable risk assessors to calcu-
late the amount of lead reduction in water,
soil, air, or diet needed to bring 95% of the
population of exposed children below the
blood lead target of 10 µg/dL (U.S. EPA
1994). It is logical that children are more toxi-
cokinetically variable than adults because of
their variable growth and maturation rates, as
well as the genetic, nutritional, disease, body
composition, and prescription (and other)
drug factors that create toxicokinetic variability
in adults. Children also present the problem of
variable growth rates, which can make even
small age bins relatively heterogeneous. Greater
variability can affect risk conclusions, especially
if one is concerned about protecting the tails
(e.g., 90th percentile) of the distribution. With
greater variability, it is also more likely that a
substantial fraction of a certain age group will
lie outside the half-log toxicokinetic variability
range we normally allocate to the adult
defaults. Thus, it is critical that a children’s
toxicokinetic assessment characterizes in some
way the degree of variability present in each age
group’s data set and determines whether that
variability is greater than in the adult case.
By addressing these questions, the risk
characterization will endeavor to determine
whether toxicokinetic differences are likely
between children and adults and whether these
differences will be important to the overall risk
assessment conclusions for this chemical/
scenario. If so, the risk characterization can
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applying qualitative (e.g., professional judg-
ment), semiquantitative (e.g., modiﬁed uncer-
tainty factors), or quantitative approaches
(PBPK modeling with distributional analyses).
The major caveats and data gaps should be
elaborated so that the limitations of the assess-
ment are clear and critical research needs are
identiﬁed. Finally, the characterization should
describe the toxicokinetic factors that appear
most inﬂuential in creating child/adult differ-
ences so that the key risk drivers for children
are explained.
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